Does Wegovy Become Less Effective as Treatment Continues?

Why the scale stops moving, and why that is not the same as Wegovy failing

When people ask whether Wegovy becomes less effective over time, they are usually noticing one of two things: the number on the scale has stopped falling, or weight loss has slowed to almost nothing. Both are normal. Semaglutide works by activating GLP-1 receptors involved in appetite signalling and gastric emptying. It reduces hunger reliably and consistently, but your body also adapts its energy expenditure as it reaches a new, lower set-point. That adaptation is metabolic, not pharmacological. The medicine has not worn off; your body has found a new equilibrium.

The STEP 1 trial (68 weeks, semaglutide 2.4mg, published in the New England Journal of Medicine) showed an average weight reduction of around 15% in participants without type 2 diabetes. Crucially, that reduction largely held through the maintenance period, the plateau was a destination, not a decline. When the trial's extension looked at what happened after stopping, participants who came off semaglutide regained most of the lost weight within a year. Their appetite returned; the medicine's absence, not its presence, was the problem.

So the honest framing is this: for most people, Wegovy does not become less effective at controlling appetite. It becomes less dramatic at producing visible scale movement, because the work is largely done. That distinction shapes every decision about what to do next.

The factors that genuinely can reduce how well Wegovy works for you personally

There are real reasons (separate from normal plateau biology) why semaglutide may feel less effective for some people. The most common is dose. Wegovy's titration pathway moves from 0.25mg through several steps to 2.4mg maintenance, with each step roughly four weeks apart. Someone who plateaued early may still be on a sub-maintenance dose; a prescriber can assess whether moving to the next step is appropriate. The approved maximum is now 7.2mg following MHRA approval of the higher-dose pen in April 2026, which may offer further reduction for some patients, though that decision rests entirely with your clinical team.

Adherence to lifestyle changes also matters. Semaglutide reduces appetite; it does not override a diet that has quietly drifted back toward old patterns. A question our prescribers hear regularly is whether the medicine has stopped working, when the more accurate picture is that calorie intake has crept up without the person noticing, the appetite suppression still exists but is now meeting more food. Reviewing what you are eating alongside treatment is genuinely useful.

Gastrointestinal side effects that led to a dose reduction or a missed injection cycle can also affect results. And, occasionally, there are people for whom semaglutide produces a smaller response from the outset, the evidence shows a distribution of outcomes, and not everyone sits at the average. If you are concerned about how well your treatment is working, that conversation belongs with your prescriber, not with a forum. If you want to explore how the evidence for semaglutide stacks up more broadly, the evidence behind semaglutide for weight loss is worth reading.

The decision most people on long-term Wegovy eventually face

Here is the practical reality: Wegovy is licensed for weight management, and the clinical evidence shows it works best as part of an ongoing rather than time-limited treatment plan, provided it remains clinically appropriate. NICE's recommendation for semaglutide (TA875) was written for NHS specialist services and specifies a maximum of two years, but that is an NHS commissioning boundary, not a biological ceiling on how long the medicine can work. Private treatment decisions are made between you and your prescriber.

The decision most people reach is whether to continue on maintenance, try a dose adjustment, or consider whether a different approach (including tirzepatide, which activates both GLP-1 and GIP receptors) might suit them better. You can read about how Wegovy works and who it is licensed for, or explore the broader evidence for semaglutide if you want the full picture before a clinical conversation. For context on what private treatment costs, the Wegovy price comparison page sets out the landscape honestly.

One practical note: if you order a repeat pen before 12pm on a working day and your prescription is approved, it goes out the same day. Having continuity in treatment matters when you are managing a long-term condition, gaps lead to the appetite signals your medicine was quieting starting to return. Keeping your prescriber informed about how treatment is progressing is the most useful thing you can do.

If you are weighing up whether to continue, adjust, or switch, a clinical review is the right next step. Check your eligibility with our prescribers, every review at nume is carried out by a real clinician, not automated software, and looks at your current position rather than applying a template.